Yuki Shundo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuki Shundo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Hirama
Division of Organ Transplantation, Tohoku University Hospital, Sendai, Japan; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
4 shared publications - Yoshinori Okada
Division of Organ Transplantation, Tohoku University Hospital, Sendai, Japan; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
4 shared publications - Tatsuaki Watanabe
Department of Thoracic Surgery, Tohoku University Hospital, Sendai, Miyagi, Japan
3 shared publications - Akihiro Ohsumi
Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
2 shared publications - Toshikazu Watanabe
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
2 shared publications - Hiromichi Niikawa
Department of Thoracic Surgery, Department of Public Health, Tohoku Medical and Pharmaceutical University, 983-8536, Japan, 1-15-1 Fukumuro, Miyagino-ku, Sendai City, Miyagi Prefecture
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108773
Infection screening at listing and vaccination management through the waiting period in lung transplant candidates in Japan
- 12 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108773
Open AccessInfection screening at listing and vaccination management through the waiting period in lung transplant candidates in Japan
- Open Access
- 1 June 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-4
Correction to: Letermovir prophylaxis for cytomegalovirus in lung‑transplant recipients: a comprehensive study with literature review of off‑label use and real‑world experiences
- 1 June 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-4
Open AccessCorrection to: Letermovir prophylaxis for cytomegalovirus in lung‑transplant recipients: a comprehensive study with literature review of off‑label use and real‑world experiences
- Open Access
- 5 April 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-9
Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences
Letermovir, initially approved for cytomegalovirus (CMV) prophylaxis in hematopoietic stem-cell transplantation, has gained attention for off-label use in lung-transplant (LTx) recipients. Given the high susceptibility of LTx recipients to CMV infection, this study explores the effectiveness and safety of letermovir prophylaxis. A retrospective analysis of using letermovir for LTx recipients at Tohoku University Hospital (January 2000 to November 2023) was conducted. Case summaries from other Japanese transplant centers and a literature review were included. Six cases at Tohoku University Hospital and one at Kyoto University Hospital were identified. Prophylactic letermovir use showed positive outcomes in managing myelosuppression and preventing CMV replication. The literature review supported the safety of letermovir in high-risk LTx recipients. Despite limited reports, our findings suggest letermovir’s potential as prophylaxis for LTx recipients intolerant to valganciclovir. Safety, especially in managing myelosuppression, positions letermovir as a promising option. However, careful consideration is important in judiciously integrating letermovir into the treatment protocol.
- 5 April 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-9
Open AccessLetermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences
Letermovir, initially approved for cytomegalovirus (CMV) prophylaxis in hematopoietic stem-cell transplantation, has gained attention for off-label use in lung-transplant (LTx) recipients. Given the high susceptibility of LTx recipients to CMV infection, this study explores the effectiveness and safety of letermovir prophylaxis. A retrospective analysis of using letermovir for LTx recipients at Tohoku University Hospital (January 2000 to November 2023) was conducted. Case summaries from other Japanese transplant centers and a literature review were included. Six cases at Tohoku University Hospital and one at Kyoto University Hospital were identified. Prophylactic letermovir use showed positive outcomes in managing myelosuppression and preventing CMV replication. The literature review supported the safety of letermovir in high-risk LTx recipients. Despite limited reports, our findings suggest letermovir’s potential as prophylaxis for LTx recipients intolerant to valganciclovir. Safety, especially in managing myelosuppression, positions letermovir as a promising option. However, careful consideration is important in judiciously integrating letermovir into the treatment protocol.
- Open Access
- 17 March 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (3) , 778
TNFR1 Mediated Apoptosis Is Protective against Mycobacterium avium in Mice
Mycobacterium avium is an intracellular proliferating pathogen that causes chronic refractory respiratory infection. Although apoptosis induced by M. avium has been reported in vitro, the role of apoptosis against M. avium infection in vivo remains unclear. Here, we investigated the role of apoptosis in mouse models of M. avium infection. Tumor necrosis factor receptor-1 knockout mice (TNFR1-KO) andTNFR2-KO micewere used. M. avium (1 × 107 cfu/body) was administered intratracheally to mice. Apoptosis in lungs was detected by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling and lung histology as well as cell death detection kits using BAL fluids. TNFR1-KO mice were susceptible to M. avium infection compared with TNFR2-KO and wild type mice based on the bacterial number and lung histology. Higher numbers of apoptotic cells were detected in the lungs of TNFR2-KO and wild-type mice were compared with TNFR1-KO mice. The inhalation of Z-VAD-FMK deteriorated M. avium infection compared with vehicle-inhaled controls. Overexpression of Iκ-B alpha by adenovirus vector attenuated M. avium infection. Our study showed apoptosis had an important role in innate immunity against M. avium in mice. The induction of apoptosis in M. avium-infected cells might be a new strategy to control M. avium infection.
- 17 March 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (3) , 778
Open AccessTNFR1 Mediated Apoptosis Is Protective against Mycobacterium avium in Mice
Mycobacterium avium is an intracellular proliferating pathogen that causes chronic refractory respiratory infection. Although apoptosis induced by M. avium has been reported in vitro, the role of apoptosis against M. avium infection in vivo remains unclear. Here, we investigated the role of apoptosis in mouse models of M. avium infection. Tumor necrosis factor receptor-1 knockout mice (TNFR1-KO) andTNFR2-KO micewere used. M. avium (1 × 107 cfu/body) was administered intratracheally to mice. Apoptosis in lungs was detected by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling and lung histology as well as cell death detection kits using BAL fluids. TNFR1-KO mice were susceptible to M. avium infection compared with TNFR2-KO and wild type mice based on the bacterial number and lung histology. Higher numbers of apoptotic cells were detected in the lungs of TNFR2-KO and wild-type mice were compared with TNFR1-KO mice. The inhalation of Z-VAD-FMK deteriorated M. avium infection compared with vehicle-inhaled controls. Overexpression of Iκ-B alpha by adenovirus vector attenuated M. avium infection. Our study showed apoptosis had an important role in innate immunity against M. avium in mice. The induction of apoptosis in M. avium-infected cells might be a new strategy to control M. avium infection.
- 17 May 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (8) , 1153-1158
Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients
- 17 May 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (8) , 1153-1158
Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients